Average Out-of-Pocket Expenses Across Different Drug Categories and Commercial Third-Party Payers

| October 31, 2010 | 0 Comments

by Susan Lenderts, BA, and Amir H. Kalali, MD
Ms. Lenderts is Associate Director, Global Commercial Partnering, Quintiles Commercial, Durham, North Carolina; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc; Professor of Psychiatry, University of California, San Diego, California.

Psychiatry (Edgemont) 2010;7(10):12–13

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , , , , , , , , , , , ,

Category: Anxiety Disorders, Attention Deficit Hyperactivity Disorder, Drug Development, Mood Disorders, Psychiatry, Psychopharmacology, Schizophrenia, Trend Watch

Leave a Reply